These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 14634389)
1. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389 [TBL] [Abstract][Full Text] [Related]
2. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Casella R; Shariat SF; Monoski MA; Lerner SP Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer. Lee KH Yonsei Med J; 2001 Feb; 42(1):14-8. PubMed ID: 11293494 [TBL] [Abstract][Full Text] [Related]
5. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628 [TBL] [Abstract][Full Text] [Related]
6. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675 [TBL] [Abstract][Full Text] [Related]
7. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433 [TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
9. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239 [TBL] [Abstract][Full Text] [Related]
10. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria. Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018 [TBL] [Abstract][Full Text] [Related]
11. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence. Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder. Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Chahal R; Darshane A; Browning AJ; Sundaram SK Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396 [TBL] [Abstract][Full Text] [Related]
14. NMP22 in transitional cell carcinoma of the urinary bladder. Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572 [TBL] [Abstract][Full Text] [Related]
15. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer. Moonen PM; Kiemeney LA; Witjes JA Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108 [TBL] [Abstract][Full Text] [Related]
16. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680 [TBL] [Abstract][Full Text] [Related]
17. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder. Jamshidian H; Kor K; Djalali M Urol J; 2008; 5(4):243-7. PubMed ID: 19101898 [TBL] [Abstract][Full Text] [Related]
18. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046 [TBL] [Abstract][Full Text] [Related]
19. Detection of recurrent bladder cancer: NMP22 test or urine cytology? Hosseini J; Golshan AR; Mazloomfard MM; Mehrsai AR; Zargar MA; Ayati M; Shakeri S; Jasemi M; Kabiri M Urol J; 2012; 9(1):367-72. PubMed ID: 22395834 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]